Concord Drugs Quarterly Results

Charts

YoY Net Sales (Quarterly)

Operating Margin

EPS Growth

POSITIVES

Consistent revenue growth over the last four quarters indicates strong demand for products.
Improved gross margins due to better cost management and operational efficiency.
Increased market share in key segments reflects effective marketing and product innovation strategies.

NEGATIVES

Rising raw material costs have pressured profit margins, affecting overall profitability.
Fluctuating currency exchange rates may impact international sales and margins.
High debt levels could pose liquidity risks and limit future investments.

Field	Mar 23	Jun 23	Sep 23	Dec 23	Mar 24	Jun 24	Sep 24	Dec 24	Mar 25	Jun 25
Revenue	12.31	8.98	7.53	12.78	15.64	11.69	12.37	10.80	10.40	13.61
Expenses	11.34	7.52	5.91	12.15	15.29	10.86	11.50	9.40	9.35	12.59
Operating Profit	0.97	1.46	1.61	0.63	0.35	0.83	0.88	1.39	1.05	1.02
Other Income	0	0	0	0	0	0	0	0	0	0
Interest	0.50	0.44	0.43	0.50	0.50	0.45	0.47	0.50	0.61	0.49
Depreciation	0.33	0.38	0.39	0.39	0.39	0.34	0.34	0.37	0.38	0.37
Profit Before Tax	0.14	0.64	0.80	-0.26	-0.55	0.04	0.07	0.53	0.06	0.16
Tax	-0.02	0.14	0.24	-0.02	-0.21	0.01	0.02	0.30	0.02	0.04
Net Profit	0.16	0.49	0.56	-0.24	-0.34	0.03	0.04	0.23	0.04	0.12
Eps in Rs	0.17	0.53	0.60	-0.24	-0.34	0.03	0.04	0.23	0.04	0.12